These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37109756)

  • 1. Systemic Juvenile Idiopathic Arthritis and Secondary Macrophage Activation Syndrome in Latvia from 2009 to 2020: A Nationwide Retrospective Study.
    Lukjanoviča K; Šlēziņa I; Dāvidsone Z; Šantere R; Budarina K; Staņēviča V
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109756
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic onset juvenile idiopathic arthritis: a single center experience.
    Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
    Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it possible to predict a disease course prone to macrophage activation syndrome at systemic juvenile idiopathic arthritis diagnosis?
    Batu ED; Sener S; Balık Z; Bayındır Y; Cam V; Kasap Cuceoglu M; Uysal O; Aliyev E; Basaran Ö; Bilginer Y; Özen S
    Clin Rheumatol; 2024 Jan; 43(1):415-421. PubMed ID: 38012469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
    Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
    Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis.
    Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Likhacheva TS; Isupova EA; Glebova NI; Kuchinskaya EM; Balbotkina EV; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
    Semin Arthritis Rheum; 2015 Feb; 44(4):417-22. PubMed ID: 25300700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease.
    Ruscitti P; Natoli V; Consolaro A; Caorsi R; Rosina S; Giancane G; Naddei R; Di Cola I; Di Muzio C; Berardicurti O; Iacono D; Pantano I; Rozza G; Rossi S; De Stefano L; Balduzzi S; Vitale A; Caso F; Costa L; Prete M; Navarini L; Iagnocco A; Atzeni F; Guggino G; Perosa F; Cantarini L; Frediani B; Montecucco C; Ciccia F; Cipriani P; Gattorno M; Giacomelli R; Ravelli A
    Rheumatology (Oxford); 2022 Oct; 61(10):4124-4129. PubMed ID: 35078234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis.
    Çakan M; Karadağ ŞG; Tanatar A; Ayaz NA
    Mod Rheumatol; 2020 Sep; 30(5):900-904. PubMed ID: 31462146
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.
    Zou LX; Zhu Y; Sun L; Ma HH; Yang SR; Zeng HS; Xiao JH; Yu HG; Guo L; Xu YP; Lu MP
    World J Pediatr; 2020 Feb; 16(1):89-98. PubMed ID: 31612427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
    Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
    J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities.
    Naveen R; Jain A; Muhammed H; Gupta L; Misra DP; Lawrence A; Agarwal V; Misra R; Aggarwal A
    Rheumatol Int; 2021 Mar; 41(3):625-631. PubMed ID: 33388903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Minoia F; Bovis F; Davì S; Horne A; Fischbach M; Frosch M; Huber A; Jelusic M; Sawhney S; McCurdy DK; Silva CA; Rigante D; Unsal E; Ruperto N; Martini A; Cron RQ; Ravelli A;
    Ann Rheum Dis; 2019 Oct; 78(10):1357-1362. PubMed ID: 31296501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment.
    Sukharomana M; Udomittipong K; Ruangchira-Urai R; Charuvanij S
    Asian Pac J Allergy Immunol; 2022 Jun; 40(2):172-176. PubMed ID: 31837211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
    Schulert GS; Yasin S; Carey B; Chalk C; Do T; Schapiro AH; Husami A; Watts A; Brunner HI; Huggins J; Mellins ED; Morgan EM; Ting T; Trapnell BC; Wikenheiser-Brokamp KA; Towe C; Grom AA
    Arthritis Rheumatol; 2019 Nov; 71(11):1943-1954. PubMed ID: 31379071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of disease course in systemic juvenile idiopathic arthritis.
    Kaplan MM; Ekici Tekin Z; Çelikel E; Güngörer V; Karagöl C; Öner N; Polat MC; Öztürk D; Özçelik E; Işıklar Ekici M; Çelikel Acar B
    Mod Rheumatol; 2024 Oct; 34(6):1238-1245. PubMed ID: 38590038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Different Diagnostic Guidelines for the Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: Single Centre Experience.
    Jelušić M; Kronja M; Frković M; Sršen S; Huljev Frković S; Štekić Novački K
    Acta Clin Croat; 2018 Jun; 57(2):307-311. PubMed ID: 30431724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.
    Barut K; Adrovic A; Sahin S; Tarcin G; Tahaoglu G; Koker O; Yildiz M; Kasapcopur O
    Int J Rheum Dis; 2019 Sep; 22(9):1661-1669. PubMed ID: 31273940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Features of Systemic Juvenile Idiopathic Arthritis in Patients With Congenital Heart Disease.
    Aires BP; Wobma H; Samad A; Chandler MT; Chang MH; Dedeoglu F; Fishman MP; Klouda T; Levin J; Halyabar O; Saleeb SF; Tworetzky W; Son MBF; Newburger JW; Casey A; Henderson LA
    J Rheumatol; 2024 Aug; 51(8):811-817. PubMed ID: 38825355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Lee PY; Schulert GS; Canna SW; Huang Y; Sundel J; Li Y; Hoyt KJ; Blaustein RB; Wactor A; Do T; Halyabar O; Chang MH; Dedeoglu F; Case SM; Meidan E; Lo MS; Sundel RP; Richardson ET; Newburger JW; Hershfield MS; Son MB; Henderson LA; Nigrovic PA
    Ann Rheum Dis; 2020 Feb; 79(2):225-231. PubMed ID: 31707357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric systemic juvenile idiopathic arthritis-related lung disease: Description of clinical cohort and review of management.
    Swanson C; Khan EK; Cooper A; Ibarra M; Tam-Williams J
    Pediatr Pulmonol; 2024 Mar; 59(3):724-733. PubMed ID: 38155594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome.
    Wu J; Sun L; Tang X; Zheng Q; Guo L; Xu L; Li Y; Lu M
    Mod Rheumatol; 2022 Oct; 32(6):1114-1121. PubMed ID: 34971386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.